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What’s already known about this topic? 
 NICE guidelines recommend annual screening for psoriatic arthritis for all 
patients with psoriasis 
 Validated screening tools, such as the Psoriasis Epidemiology Screening 
Tool (PEST), have been developed for use in adult dermatology clinics 
 No screening tools are currently recommended for use in paediatric 
dermatology clinics 
 The Paediatric Gait Arms Legs Spine (pGALS) is a quick simple validated 
musculoskeletal assessment to be used by non-specialists to distinguish 
abnormal from normal joints in children 
 
What does this study add?  
 This study shows that dermatologists are asking about joint disease but 
the current approach is not structured or standardised  
 Dermatologists suggested an assessment tool/guideline and training to 
improve early detection of juvenile psoriatic arthritis  
 There is a need to increase dermatologists confidence in paediatric 
musculoskeletal examination; this will be of particular importance if an 
examination-based screening tool such as pGALS is recommended 
 Guidance on how to screen for psoriatic arthritis in children based on the 
authors’ clinical experience.  
 
 
 
 
Abstract 
Introduction 
National Institute for Health and Care Excellence (NICE) guidelines recommend 
annual screening for psoriatic arthritis in all patients with psoriasis. Currently, no 
validated assessment tools have been recommended for screening for juvenile 
psoriatic arthritis (JPsA). Our first objective was to determine dermatologists’ 
practice when assessing children’s joints. Second, we aimed to explore the 
challenges dermatologists experience when looking for joint disease to inform 
future strategies to improve early detection of arthritis.  
 
Methods 
Structured telephone interviews were undertaken with dermatologists, identified 
through the British Society of Paediatric Dermatology. Percentages for binary 
and categorised responses were calculated. Thematic content analysis was used 
to generate a set of core themes across the interview data. 
 
Results 
Twenty three of the 41 consultant dermatologists contacted agreed to be 
interviewed. Seventy eight percent (18/23) reported they routinely ask about 
joint disease. Only 13% (3/23) routinely examine the joints of children with 
psoriasis. Overall, assessment for JPsA lacked a structured evidence-based 
approach.  
 
The average confidence rating for assessing joint disease was low (3). The two 
key barriers described for detecting arthritis were lack of experience and training 
and subtle or difficult to detect signs. The two main suggestions for improving 
detection were the introduction of an assessment tool/guideline and increased 
clinical experience and training. 
 
Conclusion 
There is a clear need for dermatologists to use a standardised approach for 
screening and to increase their confidence in paediatric musculoskeletal 
examination. Based on the authors’ experience, guidance is provided on 
screening for psoriatic arthritis in children.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Introduction 
Psoriasis affects patients of all ages. The estimated prevalence of psoriasis 
amongst children and young people is between 0.5 and 2.15% 1. Psoriatic 
arthritis is a known associated disease in patients with psoriasis 2,3 and is 
considered less common in children compared to adults. National Institute for 
Health and Care Excellence (NICE) guidelines for psoriasis recommend annual 
assessment for psoriatic arthritis 4. In adults validated screening tools are 
available for use by dermatologists, for example the Psoriasis Epidemiology 
Screening Tool (PEST) questionnaire 5, however currently there are no validated 
tools recommended for use in paediatric dermatology.  
 
Juvenile psoriatic arthritis (JPsA) is defined as an idiopathic inflammatory 
arthritis diagnosed in a child under 16 years and the presence of psoriasis or two 
out of the following criteria: family history of psoriasis in a first degree relative, 
nail pitting, onycholysis, dactylitis 6 (Figure 1). Published literature on JPsA is 
limited and the presentation can include oligoarticular, polyarticular and 
enthesitis-related arthritis 7-9. It is recognised that JPsA is a destructive 
arthropathy and can lead to permanent damage if left untreated 3,10-12. A delay 
to diagnosis in all childhood inflammatory arthropathies can result in poorer 
long-term outcomes and disability 13. Negative outcomes in JPsA include poorer 
physical health, a greater need for disease modifying medications and joint 
replacements as well as quality of life and higher unemployment 3,10,14 Therefore, 
early detection of JPsA in at risk populations is important.   
 
Our first objective was to determine dermatologists’ routine practice when 
screening for JPsA . Second, we aimed to explore the challenges 
dermatologistsexperience when assessing joints in children to inform future 
strategies to improve early detection of arthritis.  
 
 
Methods 
Elite interviews were undertaken with consultant members of the British Society 
of Paediatric Dermatology (BSPD) who manage psoriasis in children15. To ensure 
a good geographical distribution of participants and only one response per 
paediatric dermatology department 41 consultant dermatologists were 
contacted. These members had had previously in a BSPD audit or survey 
confirmed to be the consultant contact for paediatric psoriasis at that centre. An 
email invitation was sent explaining the format, purpose and intended audio 
recording of the interview. No incentive was offered for participation in the 
interviews. A telephone appointment was made with those who responded. All 
dermatologists who agreed to participate in the telephone interviews provided 
verbal consent at the beginning of the recording. To ensure anonymity, all 
participants were assigned a unique identifier in place of their real name.  Ethical 
approval was not sought as this survey of current practice and opinion and falls 
within dermatologists role as a health professional.  
 
All interviews were conducted by author EBT over a four month period between 
March and July 2015. The interviews took between 15 and 30 minutes each and 
followed a written interview guide. The guide contained open questions at the 
beginning of each interview section and closed questions to provide more 
specific details. The responses were transcribed from the audio recording as 
intelligent transcription. The interviews were analysed both quantitatively and 
qualitatively. 
 
Analysis 
Quantitative 
The interview schedule included questions on: i) dermatologists routine practice 
for assessing joint disease in children with psoriasis; ii) reasons why detecting 
JPsA may be difficult and suggestions about what would improve detection; iii) 
clinical presentation, implications for management and long-term health 
outcomes. The responses were categorised and percentages calculated for these 
and binary responses. We calculated a mean average Likert scale response for 
dermatologist’s confidence when assessing for joint disease. The scale had a 
range of 1 (not at all confident) to 10 (very confident). All quantitative data was 
analysed using basic descriptive statistics (Microsoft Excel 2010).   
 
Thematic analysis 
Thematic content analysis, using the five-steps described by Braun and Clarke 
16, was applied to the transcripts as a whole to identify common themes across 
the interviews. The first stage was familiarisation of the data, followed by 
generating initial codes, searching for themes, reviewing themes, and defining 
and naming themes. This is an established method often used in eliciting rich 
data that quantitative analysis  cannot do alone 16. 
 
Results 
Quantitative 
A total of twenty three consultant dermatologists were interviewed. A good 
geographical distribution across the UK was achieved: England (18), Wales (2), 
Scotland (2) and Northern Ireland (1). Seventeen dermatologists (74%) were 
female. Sixteen dermatologists (70%) were clinical lead for paediatric 
dermatology at their centre. Twelve (52%) worked in a secondary referral 
centre, two (9%) in a tertiary referral centre, and nine (39%) in both. The 
average number of children seen by each dermatologist with psoriasis per month 
was four (range 1 to 10).  Nine dermatologists currently have children with 
psoriasis and psoriatic arthritis under their care. 
 
 
 
Routine assessment (Table 1) 
In total 18 (78%) dermatologists routinely ask children with psoriasis about joint 
disease. Of participants who worked solely in a secondary referral centre 
(n=12), 7 (58%) routinely ask children with psoriasis about joint disease 
compared to all of those who work in a tertiary centre or both (n=11). Of these, 
13/18 (72%) ask new patients, but only four (22 %) always ask about joint 
disease at every visit and one replied often (4%). About half, 12/23 (52%), ask 
about a family history of psoriatic arthritis. The number who routinely examine 
for arthritis is low (3, (13%)).  
 
Six clinicians (26%) have used or know of a screening/assessment tool, of those 
four mentioned PEST and one cited a locally modified PEST to cover for axial 
disease. Three dermatologists who routinely examine for arthritis described their 
assessment as ‘move and feel’ with particular focus on the small joints; however 
no systematic approach was described.  
 
Barriers to assessing joint disease in children with psoriasis (Table 1) 
Inexperience and lack of training in musculoskeletal examination were identified 
as reasons why detecting arthritis may be difficult. Addressing these were the 
two main suggestions for improving detection. On average dermatologists rated 
their confidence in assessing joint disease in children at 3 (response range was 1 
to 7).  
 
Presentation of JPsA, implications for management of the skin and long-
term outcomes health outcomes (Table 2) 
Most dermatologists (70%) felt that psoriasis presents before arthritis, but many 
commented that their perception might reflect referral bias, since dermatologists 
were more likely to be referred patients with skin disease. Overall participants 
were often unsure or felt no particular pattern was associated with the 
presentation of skin (8 (35%)) or joint disease (12 (52%)).  
 
The majority (16, (70%)) of dermatologists said that the presence of JPsA would 
change their management of psoriasis. Three (13%) participants said they would 
instigate more aggressive management if JPsA was present.  
 
A relatively high proportion of participants (15, (65%)) were unsure about the 
long-term health outcomes for children with psoriasis and psoriatic arthritis and 
felt unable to base their answers in evidence or direct experience.  
 
Thematic analysis 
The qualitative analysis generated four main themes: i) identity and attitudes; ii) 
knowledge; iii) barriers to action; iv) age specific differences in managing 
children compared to adults with psoriasis. The themes are presented in Table 3. 
Respondent quotations are used to substantiate each theme and subtheme. 
Saturation of themes was achieved. In specific regard to theme 3, subtheme set 
up of paediatric services, currently none of the dermatologists interviewed offer 
a combined paediatric dermatology/rheumatology clinic at their centre, but 
many share care between the two specialties for children with skin and joint 
disease. The direct contact between consultants varied between referral by letter 
and direct contact.   
 
Discussion 
This research is the first study to detail dermatologists’ experiences of assessing 
for JPsA in children with psoriasis. The interviews demonstrate that whilst most 
clinicians routinely ask about joint disease their assessment focuses on new 
patients, asking about joint pain and relying on symptoms to prompt an 
examination. However, no structured and consistent approach to assessment 
was described.  
 
Dermatologists rated their confidence in assessing for arthritis as low. Low 
confidence was also an important subtheme in the qualitative analysis. In part, 
low confidence may originate from a lack of experience or training and concern 
that the physical signs of arthritis may be subtle or difficult to detect. These 
were the two main reasons dermatologists described as to why detecting JPsA 
may be difficult. The two key suggestions to improve detection were the 
introduction of an assessment tool/guideline and to improve clinical training and 
experience of joint assessment.  
 
A recent multicentre audit showed that dermatologists ask questions about joint 
symptoms in nearly half of children reviewed in clinic 17. These interviews 
demonstrate an improvement in the reported level of questioning about joint 
symptoms, but there is a need to formalise assessment as part of an annual 
review. 
 
Dermatologists commonly associate inflammatory arthritis with pain or soreness; 
however these may not be the most important differentiating symptoms in 
detecting inflammatory arthritis in children. Joint swelling or loss of function may 
be more indicative of the presence of joint inflammation. Clinicians would 
therefore benefit from clearer guidance about core questions to ask when 
assessing for inflammatory arthritis in the history. We recommend that 
dermatologists include the questions listed in Figure 2 when asking about joint 
disease.  
 
Currently there are no validated assessment tools recommended to screen for 
JPsA in paediatric dermatology. Paediatric rheumatologists recommend the use 
of Paediatric Gait Arms Legs Spine (pGALS) tool to screen for all types of joint 
disease in children 18. pGALS is a quick simple validated musculoskeletal 
assessment to be used by non-specialists to distinguish abnormal from normal 
joints in children, that might not be apparent from the history alone. On average 
pGALS takes 2 minutes to perform and specific manoeuvres to cover juvenile 
idiopathic arthritis are included 19. There is a full educational support package 
available online or through DVD to teach clinicians how to perform a pGALS 
examination 20. When participants were asked directly about screening or 
assessment tools to look for JPsA in children none suggested pGALS. Due to 
dermatologist’s lack of awareness  of an examination based tool and low 
confidence in assessing joint disease, successful implementation of pGALS would 
benefit a national strategy for dissemination and education amongst paediatric 
dermatologists.  
 
The Psoriasis Epidemiology Screening Tool (PEST) questionnaire 5 or a modified 
PEST had been used by five dermatologists. Its sensitivity and specificity as a 
screening tool for JPsA is unknown, and JPsA is a distinct disease from adult 
psoriatic arthritis supported by a different genetic basis and clinical 
presentation6,21. However, further evaluation of its utility as a screening tool, 
especially for adolescents, should be considered since there has already been 
early adoption amongst dermatologists.  
 
The absence of screening tool specifically designed or validated for JPsA is a 
current evidence gap and should be identified as an area of research need. It is 
unknown whether a questionnaire or examination based approach is best for use 
in paediatric dermatology clinics. In view of this lack of guidance, until further 
research is conducted, we have laid out a structure for assessing for joint 
disease in children with psoriasis based on our clinical experience (Figure 2).  
 
Current available literature is also extremely limited on the clinical presentation 
of skin and joint disease in JPsA, and the long-term outcomes for children with 
both diseases. The evidence about the temporal relationship between the onset 
of psoriasis and arthritis is varied and it is unclear if associations such as 
intergluteal/perianal, scalp and nail psoriasis with psoriatic arthritis hold true in 
the paediatric population 22,23. This correlates with dermatologists uncertainty 
and supports the genuine need for further studies to evaluate the clinical 
presentation and potential risk factors for developing psoriatic arthritis in 
childhood. 
 
The interviews were undertaken with a geographically diverse and institutionally 
varied group of dermatologists suggesting that their views and practices are 
likely to be representative of paediatric dermatologists in the UK. Interviews with 
23 participants provided a rich and detailed dataset and saturation of themes 
was achieved; this sample size is accepted for elite interview qualitative 
research15. However, it is likely that those who participated in the interviews are 
more likely to have a specialist interest in childhood psoriasis and therefore 
implement best practice. The effect of this difference would be to minimise 
rather than augment the conclusions of these interviews. No specific data was 
collected on non-responders, but geographical and gender  (74% vs 67%) 
representation was similar between both groups. Clinical assessment of psoriatic 
arthritis is not without its limitations and there is growing appreciation of the 
role ultrasound may play in the detection of subclinical enthesitis 24,25 
 
In conclusion, our findings suggest a need for a standardised and effective 
approach when screening for JPsA and for such screening to occur annually. The 
evaluation of current screening tools, either used outside dermatology (pGALS) 
or in adults (PEST), for their suitability to be used in paediatric dermatology 
clinics needs to be considered. In the interim we have provided 
recommendations for the assessment of JPsA . A closer working relationship with 
colleagues in rheumatology should be encouraged to improve dermatologists 
confidence and awareness of paediatric musculoskeletal disease.  
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Table 1: Responses to questions asked about how joint disease is routinely 
assessed, difficulties experienced when assessing for joint disease and 
suggestions to improve the detection of joint disease in children with psoriasis 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Interview question 
 
Responses 
 
Number of responses, 
n=23 (%) 
 
 
 
 
 
 
How would you ask a child 
or their parents, about 
joint disease? 
 
Ask about symptoms: 
 Pain or soreness 
 Swelling 
 Redness 
 Stiffness 
 Morning stiffness 
 Specific sites of symptoms eg 
hands, heel 
 
19 (83%) 
19 (83%) 
9   (39%) 
4   (17%) 
3   (13%) 
1   (4%) 
5   (22%) 
 
Limitations on activity 
 
 
7 (30%) 
 
Not meeting expectations 
 
6 (26%) 
 
 
Open question ‘any problems’? 
 
2 (9%) 
 
 
 
 
 
 
In your experience are 
there any reasons why you 
may find detecting 
psoriatic arthritis in 
children with psoriasis 
difficult? 
 
Lack of experience or training in joint 
assessment 
 
11 (48%) 
 
Physical signs may be subtle or difficult to 
detect in children 
 
6 (26%) 
 
Lack of awareness of the association between 
psoriasis and juvenile psoriatic arthritis by 
family and clinicians 
 
4 (17%) 
 
More difficult communication with children 
 
4 (17%) 
 
Alternative diagnoses for joint symptoms 
 
4 (17%) 
 
Other: eg rely on rheumatology, time limited 
in clinic, limited investigations 
 
5 (22%) 
 
No difficulties experienced 
 
2 (9%) 
 
 
 
 
Can you make any 
suggestions about what 
would help you detect joint 
disease in children with 
psoriasis? 
 
 
Assessment tool/guideline 
 
14 (61%) 
 
Clinical training or experience  
 
8 (35%) 
 
Other: eg  education through national 
meetings, simple investigations, improved 
identification of at risk children 
 
5 (22%) 
 
No suggestion given  
 
 
1 (4%) 
Interview question Response Number of responses, n 
(%) 
In your experience, do you feel 
skin signs or joint signs develop 
first in children with psoriatic 
arthritis? 
Psoriasis first 16 (70%) 
Unsure about order of presentation 5 (22%) 
Joints first 1 (4%) 
Simultaneous presentation 1 (4%) 
In your experience do you feel 
there are any particular skin 
patterns in children with psoriatic 
arthritis?* 
Unsure or no pattern associated 8 (35%) 
Acral 3 (13%) 
Nail 3 (13%) 
Severe psoriasis 3 (13%) 
Chronic plaque 2 (9%) 
Scalp 2 (9%) 
Less likely to occur with guttate psoriasis 2 (9%) 
Other: localised, flexural, correlation between 
sites of psoriasis and arthritis 
3 (13%) 
In your experience do you feel 
there are any particular joint 
patterns in children with psoriatic 
arthritis?* 
Unsure or no pattern associated 12 (52%) 
Small joint disease 5 (22%) 
Monoarthritis 3 (13%) 
Enthesitis 3 (13%) 
Knee 2 (9%) 
Other: Elbow, ankles, dactylitis, widespread, 
mutilating 
5 (22%) 
In your experience, what are 
about the long-term outcomes in 
children with psoriasis and 
psoriatic arthritis?* 
Unsure 12 (52%) 
More likely to have severe and persistent 
psoriasis 
11 (48%) 
Poorer compared to children with psoriasis 
alone 
6 (26%) 
Increased concern about comorbidities 4 (17%) 
Psoriasis is likely to do well on 
rheumatological drugs 
4 (17%) 
Other: increased need for aggressive 
treatment, joint disease can be disabling, 
poorer quality of life 
6 (26%) 
Table 2: Responses to questions about the clinical presentation of juvenile 
psoriatic arthritis and long-term health outcomes. *More than one response 
possible 
 
 
 
 
Table 3: Main themes and subthemes from thematic analysis of interviews 
Theme Subtheme Example participant quotations 
 
Attitude 
Confidence 
Low confidence due to limited 
training and guidance.  
 
‘I’m not that confident’ [P3] 
 
‘I don’t think I would ever be confident examining joints or be confident 
clinically’ [P9] 
 
‘I don’t regard myself as doing a proper musculoskeletal examination’ [P1]  
 
Awareness 
Opinions on ease of detecting 
juvenile psoriatic arthritis varied but 
the need for vigilance by clinicians 
and families for juvenile psoriatic 
arthritis is recognised 
 
‘I think we would be able to tell if there is a serious inflammatory joint 
problem’ [P4] 
 
‘you may not see inflammation as easily [P6] 
 
‘I do highlight to parents at the first visit that there can be a link and it is 
important if they develop any joint symptoms or signs to check it’ [P6].   
 
Division of roles  
Joint assessment and examination 
was strongly associated with 
paediatric rheumatology 
 
‘if there is evidence of arthritis I hand them off to the rheumatologists’ [P3]  
 
‘because we work so closely I’ve never really taken it on board (assessment 
of joints)’ [P1]. 
 
Knowledge 
Uncertainty 
Unsure about the clinical 
presentation and long-term health 
outcomes 
 
‘I don’t know, I haven’t seen enough to give a valid answer for that’ [P17] 
 
‘I don’t think I can answer that because I am not involved enough in follow-
up’ [P1] 
 
‘what information about psoriatic arthritis starting in children and how is the 
natural history of this condition progressing on to adulthood,  I don’t think 
there is hardly any data’ [P3]. 
 
Treatment 
Choice of treatment is influenced by 
knowledge and understanding of the 
disease 
 
‘much more likely to go to methotrexate early if they have arthritis rather 
than phototherapy’ [P2] 
 
‘in the long term their skin does better than children who are not treated 
early with a systemic’ [P1] 
Disease impact 
Disability and challenging 
management 
 
‘I have seen some horrible permanent joint deformity with very, very, 
significant impact on function’ [P6] 
 
‘you know these are going to be difficult cases for life’ [P22]. 
 
Barriers to 
action 
Signs and symptoms  
Reliance on a history of joint 
symptoms to prompt examination 
 
‘if they’ve had any joints that are sore, swollen or red’ [P9] 
 
‘if the specifically said one joint was troublesome then I would look more 
carefully at that’ [P7] 
Set-up of paediatric 
services 
Variation in the working relationship 
between specialties and opportunity 
for training 
 
‘we do a joint paediatric rheumatology-dermatology clinic every three months’ 
[P6]  
 
‘they aren’t geographically particularly close  . . . I know the name of the 
paediatric rheumatologist but I’ve never met them’ [P8]. 
 
Age 
specific 
differences 
 
Differences in consultation 
requirements and presentation of 
disease 
 
‘children won’t necessarily localise pain or be able to describe joint pain in the 
same way as an adult’ [P4] 
 
‘I think often the parental anxiety and involvement can be really difficult’ [P5] 
 
‘you may not see inflammation as easily particularly if they are chubby, little 
tiny ones’ [P6] 
Figure 1: A summary of the International League of Associations of 
Rheumatology (ILAR) diagnostic criteria for juvenile psoriatic arthritis 6 
 
 
Age at onset is under 16 years, disease duration is 6 weeks or greater, and other known 
conditions are excluded  
 
 
AND psoriasis 
 
 
OR two of the following dactylitis, nail pitting, onycholysis, and/or family history of 
psoriasis (in a first-degree relative) 
 
 
EXCLUDING  
Ankylosing spondylitis, enthesitis-related arthritis, sacroiliitis with inflammatory bowel 
disease, Reiter's syndrome, acute anterior uveitis  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: Recommendations for assessing for juvenile psoriatic arthritis in 
children with psoriasis 
 
 
Focus on the following questions in the clinical history 
 
Swelling and stiffness of joints 
 
Difficulties getting up and moving in the mornings or after a period of rest 
 
Any problems with day to day activities and taking part in sport 
 
Difficulties holding a pen or developing a swollen ‘sausage’ finger/toe 
 
 
 
Ask about a family history of psoriasis and psoriatic arthritis 
 
 
Consider performing a Paediatric Gait Arms Legs Spine (pGALS) assessment if 
undertaken relevant training 18,19 
 
Gait: Observe the patient walking 
 
Arms: Upper limb movements with specific movements for the hands 
 
Legs: Lower limb movements including the hips 
 
Spine: Movement of the whole spine 
 
 
Consider using the Psoriasis Epidemiology Screening Tool (PEST) in young 
people (12-18 years) 5 
 
 
Refer to paediatric rheumatology if any signs or symptoms elicited 
 
 
